

Clinical trials of mineralocorticoid receptor antagonists for heart failure in HF pEF

TrialResults-center www.trialresultscenter.org

1 mineralocorticoid receptor antagonists

Trial	Treatments	Patients	Trials design and methods
spironolactone vs placebo			
TOPCAT , 2014 [NCT00094302] n=3445 follow-up: 3.3 years	spironolactone (15 to 45 mg daily) versus placebo	patients with heart failure and a preserved left ventricular ejection fraction of 45% or more	Parallel groups double-blind

References

TOPCAT, 2014:

Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O'Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM Spironolactone for heart failure with preserved ejection fraction. *N Engl J Med* 2014;370:1383-92 [[24716680](https://doi.org/10.1056/NEJMoa1313731)] [10.1056/NEJMoa1313731](https://doi.org/10.1056/NEJMoa1313731)

2 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.